Risk factors and outcome in dogs with recurrent massive hepatocellular carcinoma: A Veterinary Society of Surgical Oncology case-control study.

Autor: Lapsley JM; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA., Wavreille V; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.; VetSpecialistes SA, Grand-Saconnex, Switzerland., Barry S; Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, USA., Dornbusch JA; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA., Chen C; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.; Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA., Leeper H; Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA., Bertran J; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Florida, Gainesville, Florida, USA., Scavelli D; Department of Clinical Sciences and Advanced Medicine, Matthew J. Ryan Veterinary Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Flint Animal Cancer Center and Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA., Liptak JM; Capital City Small Animal Mobile Surgery, Ottawa, Ontario, Canada.; Alta Vista Animal Hospital, Ontario, Canada., Wood C; Alta Vista Animal Hospital, Ontario, Canada., Shamir S; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA., Rosenbaum C; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Minnesota, Twin Cities, Minnesota, USA., Montinaro V; Soft Tissue Surgery Department, Clinica Veterinaria Malpensa-AniCura, Samarate, Italy., Wustefeld-Janssens B; Flint Animal Cancer Center and Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.; Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, Texas, USA., Sterman A; Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, Texas, USA.; Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, West Lafayette, Indiana, USA., Chik C; College of Veterinary Medicine, Cornell University, Ithaca, New York, USA., Singh A; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada., Collins J; Surgery Department, Metropolitan Veterinary Hospital, Copley, Ohio, USA., Selmic LE; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
Jazyk: angličtina
Zdroj: Veterinary and comparative oncology [Vet Comp Oncol] 2022 Sep; Vol. 20 (3), pp. 697-709. Date of Electronic Publication: 2022 May 15.
DOI: 10.1111/vco.12824
Abstrakt: Local recurrence after surgical excision of canine massive hepatocellular carcinoma (HCC) has been poorly studied in veterinary medicine with scant information published regarding risk factors for and outcome following recurrence. The aim of this case-control study was to describe the time to recurrence, evaluate potential risk factors for recurrence, and report the outcome in dogs with massive HCC. Medical records for 75 dogs who developed recurrence and 113 dogs who did not develop recurrence were reviewed. Statistical analyses were performed to determine risk factors for recurrence as well as the median time to develop recurrence and overall survival time (OS). None of the risk factors evaluated were significant for the development of recurrence. The median time to develop recurrence was 367 days (range 32-2096 days). There was no significant difference in median OS for dogs who developed recurrence vs. those who did not (851 vs. 970 days). For dogs with recurrent HCC, treatment at recurrence trended toward prolonged OS but was not significantly different from dogs not undergoing treatment at recurrence. There was no significant difference in median OS for dogs with histologically complete vs. incomplete tumour excision (990 vs. 903 days). Although specific risk factors for recurrence were not identified, elevations in liver values were noted in patients with recurrent disease and could act as a noninvasive surveillance tool. Recurrence was noted earlier in dogs who had routine post-operative surveillance (228 vs. 367 days). Routine surveillance for recurrence is recommended especially in dogs where further intervention is possible and should extend beyond 1 year. Patients with massive HCC have a good long-term prognosis regardless of incomplete excision, pulmonary metastasis, or recurrent local disease.
(© 2022 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje